Axovant Sciences Ltd. (NYSE:AXON) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a report released on Saturday.

Other equities research analysts have also issued research reports about the stock. Jefferies Group LLC restated a “buy” rating and issued a $31.00 target price on shares of Axovant Sciences in a research note on Friday, June 9th. Cowen and Company restated an “outperform” rating and issued a $30.00 target price on shares of Axovant Sciences in a research note on Wednesday, June 21st. CIBC upped their target price on shares of Axovant Sciences from $26.00 to $30.00 and gave the company an “outperform” rating in a research note on Wednesday, June 14th. Oppenheimer Holdings, Inc. upped their target price on shares of Axovant Sciences from $26.00 to $30.00 and gave the company an “outperform” rating in a research note on Wednesday, June 14th. Finally, Zacks Investment Research lowered shares of Axovant Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Three equities research analysts have rated the stock with a sell rating and nine have issued a buy rating to the stock. Axovant Sciences presently has an average rating of “Buy” and an average target price of $27.75.

Axovant Sciences (AXON) traded down 0.19% during trading on Friday, reaching $21.01. The company had a trading volume of 463,998 shares. The company’s market capitalization is $2.26 billion. Axovant Sciences has a 52-week low of $11.01 and a 52-week high of $26.49. The stock has a 50 day moving average price of $22.68 and a 200-day moving average price of $19.46. Axovant Sciences also was the target of some unusual options trading activity on Wednesday. Stock investors purchased 11,388 put options on the company. This represents an increase of approximately 1,108% compared to the average volume of 943 put options.

Axovant Sciences (NYSE:AXON) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by $0.12. On average, equities research analysts anticipate that Axovant Sciences will post ($2.41) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Axovant Sciences Ltd. (AXON) Downgraded by BidaskClub to Sell” was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/19/axovant-sciences-ltd-axon-downgraded-by-bidaskclub-to-sell.html.

Large investors have recently made changes to their positions in the stock. Wells Fargo & Company MN increased its stake in shares of Axovant Sciences by 1.6% in the second quarter. Wells Fargo & Company MN now owns 22,790 shares of the biotechnology company’s stock worth $528,000 after buying an additional 355 shares in the last quarter. American International Group Inc. increased its stake in shares of Axovant Sciences by 7.1% in the first quarter. American International Group Inc. now owns 15,052 shares of the biotechnology company’s stock worth $225,000 after buying an additional 998 shares in the last quarter. Legal & General Group Plc increased its stake in shares of Axovant Sciences by 20.2% in the second quarter. Legal & General Group Plc now owns 6,955 shares of the biotechnology company’s stock worth $162,000 after buying an additional 1,168 shares in the last quarter. Teachers Advisors LLC increased its stake in shares of Axovant Sciences by 5.2% in the fourth quarter. Teachers Advisors LLC now owns 41,303 shares of the biotechnology company’s stock worth $513,000 after buying an additional 2,038 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in shares of Axovant Sciences by 38.9% in the first quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock worth $111,000 after buying an additional 2,072 shares in the last quarter. 94.54% of the stock is owned by institutional investors and hedge funds.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Analyst Recommendations for Axovant Sciences (NYSE:AXON)

Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.